Potent Inhibition of Zika Virus Replication by Aurintricarboxylic Acid
In this study, we evaluated ATA as a potential antiviral drug against ZIKV replication. The antiviral activity of ATA against ZIKV replication in vitro showed median inhibitory concentrations (IC50) of 13.87 ± 1.09 μM and 33.33 ± 1.13 μM in Vero and A549 cells, respectively; without showing any cytotoxic effect in both cell lines (median cytotoxic concentration (CC50)> 1,000 μM). Moreover, ATA protected both cell types from ZIKV-induced cytopathic effect (CPE) and apoptosis in a time- and concentration-dependent manner. In addition, pre-treatment of Vero cells with ATA for up to 72 h also resulted in effective suppression of ZIKV replication with similar IC50. Importantly, the inhibitory effect of ATA on ZIKV infection was effective against strains of the African and Asian/American lineages, indicating that this inhibitory effect was not strain dependent. Overall, these results demonstrate that ATA has potent inhibitory activity against ZIKV replication and may be considered as a potential anti-ZIKV therapy for future clinical evaluation.
Introduction
Zika virus (ZIKV) belongs to the genus Flavivirus within the Flaviviridae family. ZIKV is an enveloped positive sense single-stranded RNA virus with a genome size of ∼10.7 kb that encodes a single polyprotein, which is post-translationally processed by cellular and viral proteases into three structural (capsid, C; pre-membrane, prM; and envelope, E) and seven non-structural (NS1,...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
More News: Academia | Adenocarcinoma | African Health | Allergy & Immunology | Biochemistry | Biology | Blood Transusion | Brain | Brazil Health | Breastfed | Centers for Disease Control and Prevention (CDC) | Chemistry | Child Development | Children | China Health | Conjunctivitis | Coronavirus | Cubicin | Cytology | Dengue Fever | Ebola | Ebola Vaccine | Encephalitis | Endemics | Enterovirus | Epidemics | Epidemiology | Fibrosarcoma | Food and Drug Administration (FDA) | France Health | Funding | G6PD | Ganglions | Genetics | Grants | Guillain-Barr Syndrome | Hepatitis | Hepatitis C | Hepatitis Vaccine | Influenza | Influenza Vaccine | International Medicine & Public Health | Japan Health | Laboratory Medicine | Lymphoma | Men | Microbiology | Milk | Molecular Biology | National Institutes of Health (NIH) | Neurology | Neuroscience | Nigeria Health | Outbreaks | Pain | Parasitic Diseases | Parasitology | Pathology | Penicillin | Perinatology & Neonatology | Pregnancy | Reproduction Medicine | Respiratory Medicine | SARS | Science | Serbia Health | Spain Health | Statistics | Stem Cell Therapy | Stem Cells | Study | Texas University | Thrombosis | Toxicology | Uganda Health | Urology & Nephrology | USA Health | Vaccines | Velcade | Veterinary Vaccinations | Virology | Vitamin A | West Nile Virus | WHO | Women | Yellow Fever | Yellow Fever Vaccination | Yersinia | Zika Virus